BIIB
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FBIIB.O%2Fkey-developments%2Farticle%2F2687902&ei=oIaaUqDjE4qw0AGZAw&usg=AFQjCNFFI9Js4BESG1Xfau5wy1_cConcSw
Elan Corporation PLC Announces Restructuring Of Tysabri Collaboration With Biogen Idec Inc
Wednesday, 6 Feb 2013 02:00am EST
Elan Corporation PLC announced that it has agreed to restructure the Tysabri collaboration with Biogen Idec Inc. Under the terms of the agreement, Elan will move from the current 50:50 business collaboration to an upfront payment of $3.25 billion and a double digit tiered royalty structure for the complete asset. Highlights of Transaction Upon Closing: Up front cash payment of $3.25 billion to Elan First 12 months: royalty of 12% of Tysabri global net sales (all indications) Tiered royalty structure after 12 months 18% on up to $2 billion of global net sales (all indications) 25% on over $2 billion of global net sales (all indications) Biogen Idec will have full ownership and control of Tysabri Current 50:50 collaboration will terminate Provides tax efficient capital and long term cash flow to Elan. The transaction is expected to close by the end of the second quarter 2013. Citi and Ondra Partners are acting as financial advisors to Elan. Cadwalader, Wickersham & Taft LLP and A&L Goodbody are acting as legal counsel to Elan.Â 
